A new clinical trial published in The BMJ reveals that patients with weakened heart function who receive stem cell therapy soon after a heart attack have a significantly lower risk of developing heart failure and related hospital admissions compared with those receiving standard care. Researchers suggest that this therapy could serve as a valuable adjunct to conventional treatment, helping prevent future cardiac complications.
The Growing Challenge of Heart Failure
While advances in heart attack management have improved survival rates, they have also led to an increase in post-attack heart failure cases. Recent studies hinted that stem cell therapy might reduce this risk, but robust clinical evidence was lacking. To bridge this gap, researchers examined whether delivering stem cells directly into coronary arteries shortly after a heart attack could help prevent heart failure over the long term.
Study Design and Patient Profile
The study involved 396 patients aged between 57 and 59 years, with no prior history of heart disease, treated at three teaching hospitals in Iran. All participants had experienced their first major heart attack, leading to extensive heart muscle damage and weakened left ventricular function — the heart’s primary pumping chamber.
Among them, 136 patients received an intracoronary infusion of allogenic Wharton’s jelly-derived mesenchymal stem cells within 3–7 days of their heart attack, in addition to standard medical care. The remaining 260 patients received only standard treatment. Researchers tracked participants for an average of 33 months, taking into account factors such as age, sex, smoking status, obesity, blood pressure, diabetes, and kidney health.
Promising Results in Reducing Heart Failure
The results were striking. Compared with the control group, patients who received stem cell therapy showed:
- Reduced heart failure rates: 2.77 vs 6.48 per 100 person-years
- Fewer hospital readmissions for heart failure: 0.92 vs 4.20 per 100 person-years
- Lower combined risk of cardiovascular death and readmission for heart attack or heart failure: 2.8 vs 7.16 per 100 person-years
Although the therapy did not significantly affect rates of heart attack readmission, overall mortality, or cardiovascular death, patients in the intervention group demonstrated notable improvement in heart function within six months compared with those who received standard care.
Limitations and Future Directions
As per the BMJ Group Press release, the researchers acknowledged certain limitations, such as the inability to perform a sham procedure for the control group, preventing a double-blind study design. They also did not assess heart failure biomarkers or measure the physiological effects of stem cell therapy on cardiac tissue.
Despite these limitations, the findings indicate that intracoronary infusion of mesenchymal stem cells may be an effective supplementary treatment for preventing heart failure after myocardial infarction.
Looking Ahead
The study’s authors call for additional large-scale trials to confirm these promising results and to further explore how mesenchymal stem cells aid heart repair. They emphasise the need to optimise clinical protocols to make stem cell therapy a safe and practical option for post-heart attack patients worldwide.